|
End-of-day quote
Wiener Boerse
2026-09-28
|
5-day change | 1st Jan Change | ||
| 9.150 EUR | -1.72% |
|
+5.17% | +57.65% |
Company Valuation: Novavax, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 10,817 | 883.9 | 570.2 | 1,288 | 1,092 | 1,753 | - | - |
| Change | - | -91.83% | -35.49% | 125.87% | -15.21% | 60.57% | - | - |
| Enterprise Value (EV) 1 | 9,756 | -228.1 | 169.7 | 534.5 | 1,096 | 1,972 | 2,057 | 1,753 |
| Change | - | -102.34% | 174.39% | 214.93% | 104.99% | 80.03% | 4.27% | -14.74% |
| P/E | -6.1x | -1.22x | -0.89x | -6.54x | 2.6x | -17x | -47.4x | 44.2x |
| PBR | -30.9x | -1.38x | -0.93x | -2.07x | -8.55x | -3.03x | -2.9x | - |
| PEG | - | 0x | 0x | 0.1x | -0x | 0x | 0.7x | -0x |
| Capitalization / Revenue | 9.44x | 0.45x | 0.58x | 1.89x | 0.97x | 4.7x | 6.59x | 5.68x |
| EV / Revenue | 8.51x | -0.12x | 0.17x | 0.78x | 0.98x | 5.29x | 7.73x | 5.68x |
| EV / EBITDA | - | 0.37x | -0.32x | -2.67x | 2.28x | -16.3x | -41.4x | -207x |
| EV / EBIT | -5.78x | 0.35x | -0.3x | -2.15x | 2.42x | -20x | -65.3x | 30.7x |
| EV / FCF | 36.8x | 0.45x | -0.22x | -5.33x | -4.38x | -8.69x | -43.8x | 14.7x |
| FCF Yield | 2.72% | 221% | -452% | -18.8% | -22.8% | -11.5% | -2.29% | 6.81% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -23.44 | -8.42 | -5.41 | -1.23 | 2.58 | -0.6251 | -0.2243 | 0.2403 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1,146 | 1,982 | 983.7 | 682.2 | 1,123 | 372.9 | 266.2 | 308.7 |
| EBITDA 1 | - | -615.7 | -525.3 | -200.4 | 480.4 | -120.9 | -49.65 | -8.459 |
| EBIT 1 | -1,687 | -644.7 | -566.5 | -248.9 | 452.8 | -98.6 | -31.49 | 57.14 |
| Net income 1 | -1,744 | -657.9 | -545.1 | -187.5 | 440.3 | -107.5 | -37.93 | 40.68 |
| Net Debt 1 | -1,061 | -1,112 | -400.5 | -753.4 | 3.579 | 219 | 303.2 | - |
| Reference price 2 | 143.07 | 10.28 | 4.80 | 8.04 | 6.72 | 10.63 | 10.63 | 10.63 |
| Nbr of stocks (in thousands) | 75,608 | 85,979 | 118,790 | 160,185 | 162,499 | 164,946 | - | - |
| Announcement Date | 2/28/22 | 2/28/23 | 2/28/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.26x | 5.97x | 17.88x | 0.98% | 47.97B | |
| 34.82x | 3.35x | 14.46x | -.--% | 44.5B | |
| -21.07x | 227.64x | -22.77x | -.--% | 43.93B | |
| 47.27x | 5.47x | 29.96x | -.--% | 41.03B | |
| 26.85x | 7.74x | 19.93x | 0.42% | 29.85B | |
| 35.19x | 5.78x | 26.24x | -.--% | 17.27B | |
| -61.04x | 9.99x | 243.78x | -.--% | 15.34B | |
| 25.79x | 2.21x | 9.6x | 1.04% | 15.3B | |
| Average | 15.13x | 33.52x | 42.38x | 0.3% | 31.9B | |
| Weighted average by Cap. | 19.70x | 43.80x | 26.11x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- NVAX Stock
- NVAX Stock
- Valuation Novavax, Inc.
Select your edition
All financial news and data tailored to specific country editions
